1357091-70-3

Upstream product

• 1426068-23-6 (4-benzyloxyphenyl)-N-cyclohexylcarbamate 
• 1426068-24-7 C₂₀H₂₂BrNO₃ 
• 1426068-27-0 3-(1,3,2-benzodioxaborol-2-yl)benzamide 
• 1426068-26-9 3-(1,3,2-dioxaborolan-2-yl)benzamide 
• 188665-74-9 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 351422-73-6 (3-(aminocarbonyl)phenyl)boronic acid 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 766-93-8 N-cyclohexylformamide 
• 252578-40-8 4-(benzyloxy)-3-bromophenol 
• 69455-12-5 4-benzyloxy-3-bromobenzaldehyde 
• 100-44-7 benzyl chloride 

Downstream Products

• 1357160-72-5 URB₉₃₇ 

Relevant academic research and scientific papers

Development of a Multigram synthesis of URB937, a peripherally restricted FAAH inhibitor

A new synthetic approach to URB937 was developed starting from the inexpensive and widely available 4-benzyloxyphenol. A reproducible four-step procedure, requiring no chromatographic purifications, was optimized that allowed the preparation of 100 g of URB937 in 45% overall yield.

PERIPHERALLY RESTRICTED FAAH INHIBITORS

Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R1 is a polar group. In some embodiments, R1 is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof. R2 and R3 are independently selected from the group consisting of hydrogen and substituted or unsubstituted hydrocarbyl; each R4 is independently selected from the group consisting of halogen and substituted or unsubstituted hydrocarbyl and n is an integer from 0 to 4; each R5 is independently selected from the group consisting of halo and substituted or unsubstituted hydrocarbyl and m is an integer from 0 to 3; and R6 is substituted or unsubstituted cyclohexyl; and the pharmaceutically acceptable salts thereof.